SeaStar Medical Holding Corp has filed a registration statement with the Securities and Exchange Commission to offer up to 1,767,784 shares of its common stock. This filing, dated October 30, 2026, indicates the company's strategy to enhance liquidity and provide existing stockholders with an opportunity to sell their shares.
The registration statement, filed under the Securities Act of 1933, allows for the resale of shares primarily by selling stockholders. SeaStar will not receive any proceeds from this offering, as it is solely for the benefit of the stockholders involved.
Background
SeaStar Medical Holding Corp operates within the surgical and medical instruments and apparatus industry, classified under SIC code 3841. The company is listed on the Nasdaq under the ticker symbols ICU and ICUCW. As an emerging growth company, SeaStar is subject to reduced public company reporting requirements, which may facilitate its operations and strategic initiatives.
What the Filing Says
The filing details that the shares being offered include:
- Up to 854,002 shares from the October Series A Warrants, with an exercise price of $3.616 per share.
- Up to 854,002 shares from the October Series B Warrants, also priced at $3.616 per share.
- Up to 59,780 shares from the Placement Agent Warrants, with an exercise price of $4.8325 per share.
Sales of these shares may occur at fixed prices, market prices, or negotiated prices, and the selling stockholders may employ underwriters or agents for the sale.
Impact
This registration could impact various stakeholders, including existing stockholders who may wish to liquidate their positions and new investors looking for opportunities in the medical instruments sector. The surgical and medical instruments industry as a whole may experience increased activity as companies like SeaStar seek to capitalize on market conditions.
What's Next
The filing does not specify what happens next, but it indicates that the selling stockholders may begin to sell shares once the registration becomes effective.
Read Next
3 E Network Technology Group Ltd files late 20-F report
Akari Therapeutics registers 144 billion shares for incentives
GFL Environmental reports strong Q3 2026 financial results
3 E Network Technology Group Faces Nasdaq Delisting Threat
Murphy USA reports third-quarter results, shows steady growth
Bank of America reports strong Q3 results amid market challenges








